On September 8, 2026, Lifeward Ltd. posted a September 2026 investor presentation on its Investors website and plans to use it in presentations to analysts, potential investors and other interested parties. The material matters to investors because it sets out Lifeward’s commercial platform, product pipeline, reimbursement position and strategic Partnership framework.
Key Highlights
- Lifeward cites $21.8 M in LTM Revenue as of June 30, 2026.
- The presentation identifies 4 products in development, including StrideSense and ReWalk X.
- Lifeward says its network covers 37 + countries and includes 40 + distributors.
Analysts, potential investors and other interested parties can now review Lifeward Ltd. (NASDAQ: LFWD)’s September 2026 investor presentation through the Investors section of its website. Lifeward posted the material on September 8, 2026, and plans to use it from time to time in presentations to those audiences. The presentation sets out the company’s rehabilitation platform, commercial model, product pipeline and partnership strategy.
Rehabilitation Platform Market Reach
Lifeward describes rehabilitation equipment as a $17 B market, with an estimated expansion to $27 B by 2030 at an 8 % CAGR. It places the rehabilitation robotics market at $598 M and projects that market to reach $1 B by 2030 at a 15 % CAGR. The presentation says Lifeward operates across 37 + countries with 40 + distributors and more than 7000 units deployed. Its reimbursement figures include access for approximately 46 % of Medicare Advantage enrollees, while the top 3 Medicare Advantage insurers in the United States cover 16 M lives. Lifeward says it has spent 10 + years building its reimbursement position.
Pipeline Spans Four Products
Lifeward’s current portfolio includes ReWalk for spinal cord injury mobility, AlterG for anti-gravity rehabilitation and an upper-body powered exoskeleton for stroke care. The presentation lists four products in development: StrideSense, with an anticipated 2027 commercial launch following FDA clearance; an upper-body exoskeleton in 2028; ReWalk X in 2029; and ReBoot in 2030 +. The presentation also describes ReWalk as the first FDA-cleared powered exoskeleton with Medicare coverage. It cites clinical evidence in which 76 % ambulated without assistance and a 3.3 metabolic equivalent of task level, based on 14 studies involving 111 patients. The document identifies Oratech Pharmaceuticals Ltd. as acquired from Oramed and describes an oral protein delivery platform and the ORMD-0801 oral insulin candidate. The Phase 2 B oral insulin study was pre-funded by Oramed, and the program requires management oversight.
Revenue, Cash and Growth Drivers
Lifeward reports $21.8 M in LTM revenue as of June 30, 2026, and says revenue grew 16 % in Q 2 2026 versus Q 2 2025. Cash was $11 M at June 30, 2026. The presentation identifies $24 B as future total addressable market and lists 4 products in development as growth drivers. The company also outlines a distribution strategy built around established commercial and operational channels. Its presentation says those channels are ready to integrate and launch additional devices under development, while its forward plans include internal product development and potential acquisitions of complementary rehabilitation technologies. The anticipated launch dates for the pipeline remain subject to FDA clearance, according to the presentation.



Please wait processing your request...